Navigation Links
UCLA prostate cancer research program receives $11.6 million federal grant
Date:8/7/2013

UCLA's Jonsson Comprehensive Cancer Center and the department of urology at the David Geffen School of Medicine at UCLA have been notified that their standing as a National Cancer Institute Specialized Program of Research Excellence (SPORE) site in prostate cancer has been renewed for another five years.

The UCLA program is under the leadership of principal investigator Dr. Robert Reiter, Bing Professor of Urologic Research and a member of the Jonsson Cancer Center.

This renewal marks the beginning of a third five-year cycle of funding that will support UCLA scientists' efforts to improve the prevention, detection and treatment of prostate cancer. Thirty-thousand American men are expected to die from the disease this year, and the NCI estimates that more than 238,000 men will be diagnosed with prostate cancer in 2013.

The SPORE program is a central component of NCI's efforts to spur collaborative, interdisciplinary cancer research at academic centers throughout the U.S., with the goal of translating basic research from the laboratories into patient care more quickly and effectively. The five-year, $11.6 million grant will help UCLA expand its renowned prostate cancer program, which engages researchers and clinicians from many disciplines across campus to uncover the mysteries of the disease.

"The SPORE grant will robustly continue the outstanding programs we have developed over the last two cycles of the grant and give us the resources to bring investigators together for new innovative and multidisciplinary projects with the goal of improving the way we diagnose and treat prostate cancer," said Dr. Mark Litwin, professor and chair of UCLA's department of urology.

"This renewal of the UCLA prostate SPORE is indicative of the world-class research we have on this campus," said Dr. James Economou, UCLA vice chancellor for research and professor of microbiology, immunology and molecular genetics; molecular and medical pharmacology; and surgical oncology.

"The renewal of this SPORE grant is affirmation of the leadership role UCLA continues to play in groundbreaking research on prostate cancer," said Dr. Eugene Washington, vice chancellor for health sciences and dean of the Geffen School of Medicine.

"Over the past 10 years, the UCLA prostate SPORE has had some great successes," Reiter said. "Among them have been the development of the drug enzalutamide by Dr. Charles Sawyers and Dr. Michael Jung, the identification of prostate stem cells by Dr. Owen Witte and colleagues, and the discovery and development of antibodies against the prostate stem-cell antigen gene, which have all gone from discovery through to clinical trials. Other highlights include Dr. Hong Wu's work on the PTEN tumor suppressor gene, demonstrating that the gene negatively regulates prostate cancer stem cell self-renewal, proliferation and survival, and the work of Dr. Bill Aronson and colleagues demonstrating that dietary changes can affect the growth rate of prostate tumors."

According to the NCI, SPORE grants are designed to promote collaboration among the best scientific minds. The grants bring together researchers who might not otherwise have a chance to work together. The UCLA prostate SPORE is the only one in California and one of a handful in the U.S.

The specific aims of the renewed grant are:

  • Conducting translational research to investigate what makes prostate cancer spread and become castration resistant, meaning that it does not respond to hormone therapy.

  • Targeting cancer stem cells and signaling pathways.

  • Evaluating the effects and mechanisms of dietary change in preventing prostate cancer.

  • Providing organizational infrastructure and novel technologies to support SPORE objectives.

  • Developing new research areas and supporting the careers of new researchers.

The SPORE grant will primarily fund four projects at UCLA:

  • Dr. Robert Reiter and Dr. Anna Wu will focus on translating N-cadherin-targeted antibody therapy into the clinic. N-cadherin, a protein expressed widely across prostate cancers, is required for castration-resistant prostate cancer to emerge and survive, and it therefore is considered a credentialed target treatment for prostate cancer by the NCI.

  • Dr. Hong Wu and Dr. Matthew Rettig will work to advance the management of castration-resistant prostate cancer by blocking the P13K and MAPK signaling pathways. An overarching hypothesis of this project is that prostate cancer can be classified according to alterations in signaling pathways the mechanisms that underlie the formation of tumors. Individual tumors need to be classified according to which pathways are involved and must be treated with combination treatments that prevent an alternate pathway from being activated when one is blocked.

  • Dr. Owen Witte, Dr. Matthew Rettig and Dr. Andrew Goldstein will be focusing on prostate cancer stem cells, which are thought to be resistant to castration and most conventional therapies. Their overall rational is that optimal cancer therapy requires targeting the bulk of differentiated or adult cancer cells as well as the cancer stem cells. This project will focus on targeting a gene called Trop-2, which is present on normal and malignant prostate stem cells. This is a novel approach to prostate cancer treatment.

  • Dr. Bill Aronson and Dr. Pinchas Cohen will focus on the molecular effects of diet and how diet can help prevent and manage early prostate cancer. A previous study led by Aaronson and Cohen found that a low-fat diet supplemented with fish oil could slow the growth of prostate tumors.

Jonsson Cancer Center director Dr. Judith Gasson, a professor of medicine and senior associate dean for research, said that UCLA's prostate cancer program is a shining example of the campus's excellence in interdisciplinary research.

"We'll be able to move forward more quickly now to develop new and better ways to prevent, diagnose and treat prostate cancer with the goal of saving tens of thousands of lives every year," she said.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. A Blast from the Past: a Prostate Cancer Fundraiser at the Hamptons
2. North Shore-LIJ Offering New Radium Treatment for Prostate Cancer Patients
3. Decision aids associated with increase in informed decision making about prostate cancer screening
4. Prostate cancers are fewer, smaller on walnut-enriched diet
5. Rancid Fish Oil Capsules May Partly Explain Omega-3 and Prostate Cancer Findings, Suggest Co-founders of Omega3 Innovations
6. Active surveillance may miss aggressive prostate cancers in black men
7. New study on popular prostate cancer protein provides insight into disease progression
8. Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers
9. Observation is safe, cost-saving in low-risk prostate cancer
10. New medication treats drug-resistant prostate cancer in the laboratory
11. Exposure to BPA in developing prostate increases risk of later cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental ... new patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, ... see the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, ...
(Date:3/29/2017)... OK (PRWEB) , ... March 29, 2017 , ... ... now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with ... straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, ...
(Date:3/29/2017)... ARBOR, Mich. (PRWEB) , ... ... ... Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing an ... dietary supplement industry. The organization, which plans to publish the first ANSI-approved ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... PITTSBURGH, PA (PRWEB) , ... March 29, 2017 ... ... and hassles associated with wearing oral braces. "The rubber bands used in conjunction ... he said, "so I decided to design a way to prevent this problem." ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- NetworkNewsWire Editorial Coverage  ... There are a number of ... but economic arguments also favor its legalization. The benefits include ... However, to legalize and regulate marijuana requires an ecosystem of ... ( SING Profile ), American Cannabis Company (OTC: AMMJ), Kush ...
(Date:3/29/2017)... - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical ... ended December 31, 2016 after market close on ... released later than the previous fiscal year,s results ... and balances of Apicore from the acquisition date ... date meets TSX Venture Exchange listed company requirements. ...
(Date:3/28/2017)... -- The global emerging cancer diagnostics market is expected ... to 2023 and reach a figure of $6.34 billion ... chronic disease and is affecting a huge population. Many ... report is focused on emerging cancer diagnostics market specifically ... due to factors such as: increasing number of cancer ...
Breaking Medicine Technology: